Medication review with collegial mentoring

Medication review with collegial mentoring has been studied in 1 paper since 2020: 1 trial in people. The newest paper, Jul 11, 2020: “Less Is More: The Impact of Deprescribing Psychotropic Drugs on Behavioral and Psychological Symptoms and Daily Functioning in Nursing Home Patients. Results From the Cluster-Randomized Controlled COSMOS Trial”.

Intervention

1 paper studies it3 findingsUpdated

See all 1 papers on medication review with collegial mentoring

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“Compared to control, the mean change in prescribed psychotropic drugs was reduced both in total and regular number”
Less Is More: The Impact of Deprescribing Psychotropic Drugs on Behavioral and Psychological Symptoms and Daily Functioning in Nursing Home Patients. Results From the Cluster-Randomized Controlled COSMOS TrialThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry2020doi:10.1016/j.jagp.2020.07.004

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Funder: Norges Forskningsråd
  • Human trial1

Studies in people

1 study gave medication review with collegial mentoring to people and measured what changed.

What changedDesignPeopleSource

no change: Has no effect on behavioral and psychological symptoms of dementia

up: Improves activities of daily living

Randomized trial4 months428 peoplenursing home patientsOlder adults; Patient cohortsThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, Jul 11, 2020

What did studies of medication review with collegial mentoring find?

3

Studies of medication review with collegial mentoring measured 3 outcomes: activities of daily living, behavioral and psychological symptoms of dementia and psychotropic drugs.

Activities of daily living

upin humans1

1 study
  1. Medication review with collegial mentoring improves activities of daily living in humans.

    “Mean change in PSMS showed improvement in the intervention group, and deterioration in the control group”

    Human trial4 monthsn = 428

    Less Is More: The Impact of Deprescribing Psychotropic Drugs on Behavioral and Psychological Symptoms and Daily Functioning in Nursing Home Patients. Results From the Cluster-Randomized Controlled COSMOS Trial

    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry

Behavioral and psychological symptoms of dementia

no changein humans1

1 study
  1. Medication review with collegial mentoring showed no clear effect on behavioral and psychological symptoms of dementia in humans.

    “mean changes in NPI-NH and CSDD scores did not differ between the groups”

    Human trial4 monthsn = 428

    Less Is More: The Impact of Deprescribing Psychotropic Drugs on Behavioral and Psychological Symptoms and Daily Functioning in Nursing Home Patients. Results From the Cluster-Randomized Controlled COSMOS Trial

    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry

More on Behavioral and psychological symptoms of dementia

Psychotropic drugs

downin humans1

1 study
  1. Medication review with collegial mentoring decreases psychotropic drugs in humans.

    “Compared to control, the mean change in prescribed psychotropic drugs was reduced both in total and regular number”

    Human trial4 monthsn = 428

    Less Is More: The Impact of Deprescribing Psychotropic Drugs on Behavioral and Psychological Symptoms and Daily Functioning in Nursing Home Patients. Results From the Cluster-Randomized Controlled COSMOS Trial

    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry

More on Psychotropic drugs

Latest